D
David C. Klonoff
Researcher at University of California, San Francisco
Publications - 329
Citations - 10879
David C. Klonoff is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 44, co-authored 277 publications receiving 8629 citations. Previous affiliations of David C. Klonoff include Syracuse University & Tokyo University of Agriculture and Technology.
Papers
More filters
Journal ArticleDOI
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C. Klonoff,John B. Buse,Loretta L. Nielsen,Xuesong Guan,Christopher L. Bowlus,John H. Holcombe,Matthew Wintle,David G. Maggs +7 more
TL;DR: Adjunctive exenatide treatment for > or = 3 years in T2DM patients resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.
Journal ArticleDOI
Continuous glucose monitoring: roadmap for 21st century diabetes therapy.
TL;DR: This report discusses continuous glucose monitoring in terms of its purposes, technologies, target populations, accuracy, clinical indications, outcomes, and problems.
Journal ArticleDOI
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Richard M. Bergenstal,David C. Klonoff,Satish K. Garg,Bruce W. Bode,Melissa Meredith,Robert H. Slover,Andrew J. Ahmann,John B. Welsh,Scott W. Lee,Francine R. Kaufman +9 more
TL;DR: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values.
Journal ArticleDOI
Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States.
Bruce W. Bode,Valerie Garrett,Jordan Messler,Raymie McFarland,Jennifer Crowe,Robby Booth,David C. Klonoff +6 more
TL;DR: This retrospective observational study of laboratory-confirmed COVID-19 adults evaluated glycemic and clinical outcomes in patients with and without diabetes and/or acutely uncontrolled hyperglycemia hospitalized March 1 to April 6, 2020, finding that patients with diabetes and or uncontrolled hyper glycemia had a longer LOS and markedly higher mortality than patients without diabetes.
Journal ArticleDOI
An economic analysis of interventions for diabetes.
David C. Klonoff,D M Schwartz +1 more
TL;DR: Widely practiced interventions for patients with diabetes can be clearly cost-saving and Clearly cost-effective, and these practices are attractive from both a medical and an economic perspective.